https://it.gsk.com/it-it/ 2026-06-03T16:24:26.627Z https://it.gsk.com/it-it/azienda/ 2026-06-03T16:24:27.593Z https://it.gsk.com/it-it/azienda/scopo-strategia-e-cultura/ 2026-06-03T16:24:28.517Z https://it.gsk.com/it-it/azienda/gsk-in-italia/ 2026-06-03T16:24:46.7Z https://it.gsk.com/it-it/azienda/gsk-in-italia/le-nostre-sedi/ 2026-06-03T16:24:49.36Z https://it.gsk.com/it-it/azienda/gsk-in-italia/la-nostra-storia/ 2026-06-03T16:24:49.71Z https://it.gsk.com/it-it/azienda/gsk-in-italia/organizzazione-locale/ 2026-06-03T16:24:48.553Z https://it.gsk.com/it-it/azienda/gsk-in-italia/il-valore-di-gsk-in-italia/ 2026-06-03T16:24:47.57Z https://it.gsk.com/it-it/azienda/policy/ 2026-06-03T16:25:08.277Z https://it.gsk.com/it-it/innovazione/ 2026-06-03T16:25:09.07Z https://it.gsk.com/it-it/innovazione/aree-terapeutiche/ 2026-06-03T16:25:08.687Z https://it.gsk.com/it-it/innovazione/gli-studi-clinici/ 2026-06-03T16:25:07.85Z https://it.gsk.com/it-it/innovazione/gli-studi-clinici/studi-osservazionali-informazioni-e-tutela-dei-pazienti/ 2026-06-03T16:25:07.53Z https://it.gsk.com/it-it/innovazione/il-sostegno-alle-proposte-di-ricerca-indipendente-iss/ 2026-06-03T16:25:21.013Z https://it.gsk.com/it-it/prodotti/ 2025-08-08T18:12:15.323Z https://it.gsk.com/it-it/prodotti/i-nostri-prodotti-in-ordine-alfabetico/ 2026-06-03T16:25:20.697Z https://it.gsk.com/it-it/prodotti/le-patologie-di-cui-ci-occupiamo/ 2026-06-03T16:25:19.8Z https://it.gsk.com/it-it/prodotti/le-risposte-sui-prodotti-gsk/ 2026-06-03T16:25:18.597Z https://it.gsk.com/it-it/prodotti/la-farmacovigilanza/ 2026-06-03T16:27:31.593Z https://it.gsk.com/it-it/responsabilita/ 2026-06-03T16:25:33.29Z https://it.gsk.com/it-it/responsabilita/inclusione/ 2026-06-03T16:25:33.69Z https://it.gsk.com/it-it/responsabilita/standard-etici/ 2026-06-03T16:25:34.087Z https://it.gsk.com/it-it/responsabilita/standard-etici/la-collaborazione-con-gli-operatori-sanitari/ 2026-06-03T16:27:32.26Z https://it.gsk.com/it-it/responsabilita/standard-etici/efpia-disclosure/ 2026-06-03T16:25:54.063Z https://it.gsk.com/it-it/responsabilita/standard-etici/la-collaborazione-con-le-associazioni-di-pazienti/ 2026-06-03T16:25:52.207Z https://it.gsk.com/it-it/responsabilita/il-volontariato-d-impresa/ 2026-06-03T16:25:53.373Z https://it.gsk.com/it-it/responsabilita/il-siena-vaccines-science-centre/ 2026-06-03T16:25:53.053Z https://it.gsk.com/it-it/responsabilita/le-campagne-di-sensibilizzazione/ 2026-06-03T16:25:52.683Z https://it.gsk.com/it-it/responsabilita/leggere-per-crescere/ 2026-06-03T16:26:06.203Z https://it.gsk.com/it-it/responsabilita/leggere-per-crescere/le-news-di-leggere-per-crescere/ 2025-08-11T16:25:51.223Z https://it.gsk.com/it-it/media/ 2026-06-03T16:26:05.91Z https://it.gsk.com/it-it/media/comunicati-stampa/ 2026-06-03T16:26:07.69Z https://it.gsk.com/it-it/media/comunicati-stampa/hiv-da-parma-innovazione-industria-e-cure-per-i-pazienti-di-tutto-il-mondo/ 2026-06-03T16:26:04.03Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-un-azienda-moderna-non-puo-fare-a-meno-di-diversita-e-inclusione/ 2026-06-03T16:26:25Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-ancora-prima-nell-access-to-medicine-index/ 2026-06-03T16:26:23.927Z https://it.gsk.com/it-it/media/comunicati-stampa/lupus-adesso-basta-un-iniezione-alla-settimana/ 2026-06-03T16:26:23.597Z https://it.gsk.com/it-it/media/comunicati-stampa/i-rapporti-di-gsk-con-gli-operatori-e-le-organizzazioni-sanitarie/ 2026-06-03T16:27:30.847Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-completa-lacquisizione-di-tesaro-unazienda-biofarmaceutica-focalizzata-sulloncologia-1/ 2026-06-03T16:26:22.867Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-e-merck-kgaa-darmstadt-germania-annunciano-unalleanza-globale/ 2026-06-03T16:26:41.567Z https://it.gsk.com/it-it/media/comunicati-stampa/i-dati-dello-studio-garnet-indicano-una-robusta-attivita-di-dostarlimab-in-pazienti-con-carcinoma-endometriale-avanzato-o-ricorrente/ 2026-06-03T16:26:40.787Z https://it.gsk.com/it-it/media/comunicati-stampa/per-la-terapia-della-bpco-vale-la-regola-del-tre-in-uno/ 2026-06-03T16:26:41.19Z https://it.gsk.com/it-it/media/comunicati-stampa/comunicato-stampa-21-03-2019/ 2026-06-03T16:26:40.077Z https://it.gsk.com/it-it/media/comunicati-stampa/comunicato-stampa-del-28-marzo-2019/ 2026-06-03T16:27:31.923Z https://it.gsk.com/it-it/media/comunicati-stampa/comunicato-stampa-02-05-2019/ 2026-06-03T16:27:31.293Z https://it.gsk.com/it-it/media/comunicati-stampa/comunicato-stampa-15-giugno-2019/ 2026-06-03T16:26:53.983Z https://it.gsk.com/it-it/media/comunicati-stampa/comunicato-stampa-del-24-09-2019/ 2026-06-03T16:26:53.597Z https://it.gsk.com/it-it/media/comunicati-stampa/lo-studio-prima-di-fase-3-su-niraparib-e-il-primo-studio-a-dimostrare-che-un-inibitore-parp-migliora-significativamente-la-pfs/ 2026-06-03T16:26:52.93Z https://it.gsk.com/it-it/media/comunicati-stampa/sindrome-ipereosinofila-mepolizumab-e-il-primo-farmaco-a-ridurre-le-riacutizzazioni/ 2026-06-03T16:27:44.797Z https://it.gsk.com/it-it/media/comunicati-stampa/lo-studio-registrativo-dreamm-2-ha-dimostrato-un-tasso-di-risposta-globale-clinicamente-significativo/ 2026-06-03T16:29:23.36Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-affida-la-licenza-del-candidato-vaccino-per-la-tubercolosi-al-bill-melinda-gates-medical-research-institute-per-la-prosecuzione-dello-sviluppo/ 2026-06-03T16:29:24.177Z https://it.gsk.com/it-it/media/comunicati-stampa/dottorato-ad-honorem-per-rino-rappuoli/ 2026-06-03T16:29:23.05Z https://it.gsk.com/it-it/media/comunicati-stampa/mieloma-multiplo-recidivante-e-refrattario-l-ema-valutera-l-immissione-accelerata-in-commercio-di-belantamab-mafodotin/ 2026-06-03T16:29:24.477Z https://it.gsk.com/it-it/media/comunicati-stampa/cepi-e-gsk-annunciano-una-collaborazione/ 2026-06-03T16:29:29.01Z https://it.gsk.com/it-it/media/comunicati-stampa/ema-ha-convalidato-la-sottomissione-della-richiesta-per-la-maa-di-niraparib/ 2026-06-03T16:29:46.09Z https://it.gsk.com/it-it/media/comunicati-stampa/aiutiamoglieroi-e-il-progetto-di-gsk-italia-e-dei-suoi-dipendenti-per-affrontare-l-emergenza-covid19/ 2026-06-03T16:29:44.567Z https://it.gsk.com/it-it/media/comunicati-stampa/mepolizumab-studio-synapse/ 2026-06-03T16:29:45.323Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-e-vir-biotechnology-si-alleano-per-individuare-nuove-soluzioni-contro-il-coronavirus/ 2026-06-03T16:29:45.783Z https://it.gsk.com/it-it/media/comunicati-stampa/sanofi-e-gsk-collaborazione-vaccinale-per-combattere-covid-19/ 2026-06-03T16:29:44.947Z https://it.gsk.com/it-it/media/comunicati-stampa/noi-per-t-r-e-gsk-per-le-pazienti-i-loro-familiari-e-gli-operatori-sanitari-che-ogni-giorno-sfidano-i-tumori-ginecologici/ 2026-06-03T16:30:05.39Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-annuncia-lintenzione-di-produrre-1-miliardo-di-dosi-di-adiuvante/ 2026-06-03T16:30:03.827Z https://it.gsk.com/it-it/media/comunicati-stampa/studi-dreamm-2-e-dreamm-6-belantamab-mafodotin-mieloma-multiplo/ 2026-06-03T16:30:03.217Z https://it.gsk.com/it-it/media/comunicati-stampa/fabio-landazabal-alla-guida-di-gsk-pharma-in-italia/ 2026-06-03T16:30:04.787Z https://it.gsk.com/it-it/media/comunicati-stampa/aggiornamento-della-schedula-vaccinale-europea-per-il-vaccino-contro-il-meningococco-b-a-4-componenti/ 2026-06-03T16:30:04.38Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-investe-in-innovazione-a-siena-nuovo-trd-smart-lab/ 2026-06-03T16:30:26.893Z https://it.gsk.com/it-it/media/comunicati-stampa/fabio-landazabal-nel-comitato-di-presidenza-di-farmindustria/ 2026-06-03T16:30:26.583Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-medicago-collaborazione-per-candidato-vaccino-adiuvato-covid-19/ 2026-06-03T16:30:26.217Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-e-curevac-annunciano-una-collaborazione-strategica-usando-la-tecnologia-mrna/ 2026-06-03T16:30:27.62Z https://it.gsk.com/it-it/media/comunicati-stampa/parere-positivo-del-chmp-su-belantamab-mafodotin-per-il-trattamento-del-mieloma-multiplo-recidivato-e-refrattario/ 2026-06-03T16:30:27.267Z https://it.gsk.com/it-it/media/comunicati-stampa/approvazione-europea-belantamab-mafodotin/ 2026-06-03T16:30:34.053Z https://it.gsk.com/it-it/media/comunicati-stampa/terapia-domiciliare-per-l-asma-severo-eosinofilo/ 2026-06-03T16:30:33.007Z https://it.gsk.com/it-it/media/comunicati-stampa/sanofi-gsk-accordo-con-unione-europea-vaccino-covid-19/ 2026-06-03T16:30:33.583Z https://it.gsk.com/it-it/media/comunicati-stampa/positive-opinion-chmp-niraparib-1l-carcinoma-ovarico/ 2026-06-03T16:35:06.707Z https://it.gsk.com/it-it/media/comunicati-stampa/formazione-e-innovazione-nello-stabilimento-gsk-di-parma/ 2026-06-03T16:35:05.707Z https://it.gsk.com/it-it/media/comunicati-stampa/vir-biotechnology-e-gsk-annunciano-l-espansione-globale-alla-fase-3-dello-studio-comet-ice-che-valuta-vir-7831-per-il-trattamento-di-covid-19/ 2026-06-03T16:30:51.31Z https://it.gsk.com/it-it/media/comunicati-stampa/indagine-sulle-richieste-delle-persone-con-hiv-in-italia/ 2026-06-03T16:30:50.073Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-presenta-i-dati-clinici-candidati-vaccini-rsv/ 2026-06-03T16:30:49.22Z https://it.gsk.com/it-it/media/comunicati-stampa/sanofi-e-gsk-supporteranno-covax-con-200-milioni-di-dosi-di-vaccino-covid-19/ 2026-06-03T16:30:50.6Z https://it.gsk.com/it-it/media/comunicati-stampa/la-commissione-europea-approva-niraparib/ 2026-06-03T16:35:07.047Z https://it.gsk.com/it-it/media/comunicati-stampa/nuovi-obiettivi-ambientali-per-gsk/ 2026-06-03T16:31:08.663Z https://it.gsk.com/it-it/media/comunicati-stampa/i-progressi-di-belantamab-mafodotin-al-congresso-ash/ 2026-06-03T16:31:06.427Z https://it.gsk.com/it-it/media/comunicati-stampa/medicago-e-gsk-partenza-studi-clinici-di-fase-23-candidato-vaccino-adiuvato-covid-19/ 2026-06-03T16:31:09.117Z https://it.gsk.com/it-it/media/comunicati-stampa/studio-di-fase-3-su-candidato-vaccino-rsv-donne-in-gravidanza/ 2026-06-03T16:31:09.673Z https://it.gsk.com/it-it/media/comunicati-stampa/sanofi-e-gsk-annunciano-un-ritardo-nel-loro-programma-di-vaccino-covid-19/ 2026-06-03T16:35:06.037Z https://it.gsk.com/it-it/media/comunicati-stampa/vir-biotechnology-e-gsk-annunciano-linizio-dello-studio-activ-3/ 2026-06-03T16:31:17.867Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-continua-ad-investire-a-rosia-con-18-milioni-di-euro-per-nuove-tecnologie-e-processi-produttivi/ 2026-06-03T16:31:19.35Z https://it.gsk.com/it-it/media/comunicati-stampa/vir-biotechnology-e-gsk-annunciano-studio-per-trattamento-precoce-covid-19/ 2026-06-03T16:35:22.577Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-si-conferma-prima-nellaccess-to-medicine-index/ 2026-06-03T16:35:21.86Z https://it.gsk.com/it-it/media/comunicati-stampa/lilly-vir-biotechnology-e-gsk-annunciano-il-primo-paziente-dello-studio-blaze-4-in-trattamento-per-covid-19/ 2026-06-03T16:35:06.323Z https://it.gsk.com/it-it/media/comunicati-stampa/collaborazione-gsk-curevac-vaccini-mrna-contro-covid-19/ 2026-06-03T16:31:33.6Z https://it.gsk.com/it-it/media/comunicati-stampa/avvio-studi-clinici-fase-iii-candidato-vaccino-rsv/ 2026-06-03T16:35:22.857Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-e-vir-biotechnology-annunciano-espansione-collaborazione-per-terapie-influenza-e-virus-respiratori/ 2026-06-03T16:31:31.91Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-e-sanofi-studio-fase-2-candato-vaccino-contro-covid-19/ 2026-06-03T16:31:33.1Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-per-i-pazienti-patient-support-programme/ 2026-06-03T16:35:22.27Z https://it.gsk.com/it-it/media/comunicati-stampa/presentati-i-risultati-dellanticorpo-monoclonale-di-gsk-otilimab/ 2026-06-03T16:31:49.89Z https://it.gsk.com/it-it/media/comunicati-stampa/chmp-raccomanda-approvazione-di-dostarlimab-per-il-carcinoma-endometriale-ricorrente-o-avanzato/ 2026-06-03T16:31:50.27Z https://it.gsk.com/it-it/media/comunicati-stampa/importante-finanziamento-a-gvgh-da-carb-x-per-lotta-antimicrobicoresistenza/ 2026-06-03T16:31:49.35Z https://it.gsk.com/it-it/media/comunicati-stampa/vir-7831-riduce-lospedalizzazione-e-il-rischio-di-morte-nel-trattamento-precoce-degli-adulti-con-covid-19/ 2026-06-03T16:31:48.927Z https://it.gsk.com/it-it/media/comunicati-stampa/medicago-e-gsk-iniziano-fase-3-vaccino-adiuvato-covid-19/ 2026-06-03T16:31:50.98Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-avvia-il-primo-studio-di-fase-3-a-per-i-pazienti-con-asma-grave/ 2026-06-03T16:36:19.227Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-e-vir-biotechnology-annunciano-richiesta-di-autorizzazione-alluso-di-emergenza-alla-fda-per-vir-7831/ 2026-06-03T16:36:19.893Z https://it.gsk.com/it-it/media/comunicati-stampa/lilly-vir-biotechnology-e-gsk-annunciano-dati-studio-di-fase-2-blaze-4-contro-covid-19/ 2026-06-03T16:36:18.57Z https://it.gsk.com/it-it/media/comunicati-stampa/arriva-in-italia-il-primo-trattamento-per-l-asma-grave-eosinofilico-refrattario-nei-bambini/ 2026-06-03T16:36:17.693Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-italia-e-una-health-friendly-company-un-ulteriore-traguardo-come-modern-employer/ 2026-06-03T16:36:18.047Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-e-vir-continuano-le-discussioni-con-gli-enti-regolatori-per-rendere-disponibile-vir-7831-contro-covid-19/ 2026-06-03T16:36:36.7Z https://it.gsk.com/it-it/media/comunicati-stampa/al-via-la-prevenzionenonhaetait/ 2026-06-03T16:36:37.967Z https://it.gsk.com/it-it/media/comunicati-stampa/la-commissione-europea-approva-dostarlimab/ 2026-06-03T16:36:35.817Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-prima-farmaceutica-nella-classifica-linkedin/ 2026-06-03T16:36:36.137Z https://it.gsk.com/it-it/media/comunicati-stampa/arriva-in-italia-nuovo-vaccino-ricombinante-adiuvato-contro-herpes-zoster/ 2026-06-03T16:36:36.423Z https://it.gsk.com/it-it/media/comunicati-stampa/approvazione-ce-belimumab-per-pazienti-adulti-con-nefrite-lupica-attiva/ 2026-06-03T16:36:52.357Z https://it.gsk.com/it-it/media/comunicati-stampa/il-candidato-vaccino-sanofi-e-gsk-covid-19-dimostra-una-forte-risposta-immunitaria/ 2026-06-03T16:36:53.087Z https://it.gsk.com/it-it/media/comunicati-stampa/medicago-e-gsk-annunciano-risultati-intermedi-positivi-per-candidato-vaccino-covid-19-adiuvato/ 2026-06-03T16:39:29.283Z https://it.gsk.com/it-it/media/comunicati-stampa/parere-positivo-ema-su-sotrovimab-di-gsk-e-vir-biotechnology-per-il-trattamento-precoce-di-covid-19/ 2026-06-03T16:36:52.703Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-e-vir-biotechnology-annunciano-autorizzazione-per-luso-di-emergenza-di-sotrovimab-vir-7831-dalla-fda-statunitense/ 2026-06-03T16:36:52.03Z https://it.gsk.com/it-it/media/comunicati-stampa/bpco-la-combinazione-ottimale-farmacodispositivo/ 2026-06-03T16:37:07.897Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-rosia-inaugura-la-nuova-area-dedicata-alla-formazione/ 2026-06-03T16:39:33.183Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-e-vir-biotechnology-annunciano-accordoappalto-congiunto-con-la-ce-per-sotrovimab/ 2026-06-03T16:39:28.837Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-presenta-a-esmo-i-progressi-della-pipeline-oncologica/ 2026-06-03T16:37:07.017Z https://it.gsk.com/it-it/media/comunicati-stampa/parere-positivo-chmp-approvazione-mepolizumab-in-tre-ulteriori-malattie/ 2026-06-03T16:37:07.397Z https://it.gsk.com/it-it/media/comunicati-stampa/oms-raccomanda-vaccino-gsk-contro-la-malaria/ 2026-06-03T16:37:20.327Z https://it.gsk.com/it-it/media/comunicati-stampa/studio-somministrazione-intramuscolare-di-sotrovimab-per-il-trattamento-precoce-di-covid-19-raggiunge-endpoint-primario/ 2026-06-03T16:39:32.633Z https://it.gsk.com/it-it/media/comunicati-stampa/mepolizumab-approvato-dalla-commissione-europea-in-tre-ulteriori-malattie-causate-da-eosinofili/ 2026-06-03T16:37:19.287Z https://it.gsk.com/it-it/media/comunicati-stampa/un-missile-teleguidato-contro-il-mieloma-multiplo/ 2026-06-03T16:37:18.027Z https://it.gsk.com/it-it/media/comunicati-stampa/i-dati-preclinici-dimostrano-che-sotrovimab-mantiene-lattivita-contro-le-mutazioni-chiave-di-omicron/ 2026-06-03T16:39:32.293Z https://it.gsk.com/it-it/media/comunicati-stampa/niraparib-disponibile-come-trattamento-di-mantenimento-in-prima-linea-del-carcinoma-ovarico-avanzato/ 2026-06-03T16:37:37.177Z https://it.gsk.com/it-it/media/comunicati-stampa/sotrovimab-mantiene-lattivita-contro-lintera-combinazione-di-mutazioni-nella-proteina-spike-della-variante-omicron-sars-cov-2/ 2026-06-03T16:37:36.413Z https://it.gsk.com/it-it/media/comunicati-stampa/ash-2021-nuovi-dati-di-belantamab-mafodotin-nel-trattamento-del-mieloma-multiplo/ 2026-06-03T16:37:37.47Z https://it.gsk.com/it-it/media/comunicati-stampa/sotrovimab-ha-ottenuto-lautorizzazione-dalla-commissione-europea-per-il-trattamento-precoce-del-covid-19/ 2026-06-03T16:37:36.73Z https://it.gsk.com/it-it/media/comunicati-stampa/arriva-app-vik-tumore-ovarico/ 2026-06-03T16:37:37.85Z https://it.gsk.com/it-it/media/comunicati-stampa/i-giovani-e-la-sfida-all-hiv-progetto-d-informazione-per-le-scuole-superiori/ 2026-06-03T16:37:51.99Z https://it.gsk.com/it-it/media/comunicati-stampa/haleon-la-nuova-azienda-che-nascera-dallo-spin-off-della-divisione-consumer-healthcare-gsk/ 2026-06-03T16:37:52.873Z https://it.gsk.com/it-it/media/comunicati-stampa/herpes-zoster-piu-del-90-degli-over-50-ha-gia-contratto-il-virus-ma-solo-il-7-si-sente-a-rischio/ 2026-06-03T16:37:53.313Z https://it.gsk.com/it-it/media/comunicati-stampa/belimumab-nefrite-lupica/ 2026-06-03T16:37:51.067Z https://it.gsk.com/it-it/media/comunicati-stampa/allasma-non-lasciare-la-prima-mossa-gioca-danticipo/ 2026-06-03T16:37:50.693Z https://it.gsk.com/it-it/media/comunicati-stampa/tumore-ovarico-con-niraparib-triplicata-la-sopravvivenza-libera-da-malattia/ 2026-06-03T16:38:11.643Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-annuncia-dati-di-fase-iii-vaccino-rsv-negli-anziani/ 2026-06-03T16:38:11.993Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-annuncia-un-investimento-di-1-miliardo-di-sterline-in-ricerca-e-sviluppo-in-10-anni-per-le-malattie-infettive-nei-pvs/ 2026-06-03T16:38:12.367Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-investe-in-innovazione-inaugurato-a-siena-il-nuovo-trd-smart-lab/ 2026-06-03T16:39:49.84Z https://it.gsk.com/it-it/media/comunicati-stampa/prevenzione-e-innovazione-per-la-salute-del-futuro/ 2026-06-03T16:38:11.257Z https://it.gsk.com/it-it/media/comunicati-stampa/tumore-dell-endometrio-in-italia-disponibile-dostarlimab-la-prima-immunoterapia-su-misura-per-le-pazienti-con-malattia-ricorrente-e-avanzata/ 2026-06-03T16:38:23.613Z https://it.gsk.com/it-it/media/comunicati-stampa/bpco-l-efficacia-delle-terapie-gsk-per-i-pazienti-aumentano-la-funzionalita-polmonare-e-diminuiscono-le-riacutizzazioni/ 2026-06-03T16:38:23.097Z https://it.gsk.com/it-it/media/comunicati-stampa/niraparib-mostra-un-beneficio-duraturo-in-termini-di-sopravvivenza/ 2026-06-03T16:38:24.92Z https://it.gsk.com/it-it/media/comunicati-stampa/loms-concede-la-prequalifica-a-mosquirix-di-gsk-il-primo-e-unico-vaccino-contro-la-malaria-approvato-al-mondo/ 2026-06-03T16:40:44.84Z https://it.gsk.com/it-it/media/comunicati-stampa/tic-toc-la-gentilezza-del-tempo-una-web-series-per-raccontare-il-mieloma-multiplo/ 2026-06-03T16:38:25.59Z https://it.gsk.com/it-it/media/comunicati-stampa/evidenze-sul-candidato-vaccino-contro-il-virus-respiratorio-sinciziale-rsv-di-gsk/ 2026-06-03T16:38:56.83Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-annuncia-una-collaborazione-ampliata-con-tempus-nella-medicina-di-precisione-per-accelerare-la-ricerca-e-lo-sviluppo/ 2026-06-03T16:39:50.517Z https://it.gsk.com/it-it/media/comunicati-stampa/nuovi-dati-sul-vaccino-ricombinante-contro-l-herpes-zoster/ 2026-06-03T16:39:50.22Z https://it.gsk.com/it-it/media/comunicati-stampa/un-diario-di-bordo-per-non-perdere-di-vista-la-bpco/ 2026-06-03T16:40:01.97Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-in-testa-all-access-to-medicine-index/ 2026-06-03T16:40:43.823Z https://it.gsk.com/it-it/media/comunicati-stampa/presentati-allash-nuovi-dati-per-i-pazienti-affetti-da-mielofibrosi-trattati-con-momelotinib/ 2026-06-03T16:41:36.697Z https://it.gsk.com/it-it/media/comunicati-stampa/lupus-parola-d-ordine-proteggere-i-reni/ 2026-06-03T16:41:37.273Z https://it.gsk.com/it-it/media/comunicati-stampa/new-england-journal-of-medicine-rafforza-il-potenziale-del-candidato-vaccino-gsk-per-la-prevenzione-del-virus-respiratorio-sinciziale-negli-adulti-anziani/ 2026-06-03T16:41:36.36Z https://it.gsk.com/it-it/media/comunicati-stampa/shingle-awareness-week-solo-un-intervistato-su-due-consapevole-della-gravita-dell-herpes-zoster/ 2026-06-03T16:41:41.303Z https://it.gsk.com/it-it/media/comunicati-stampa/una-webserie-per-raccontare-i-tumori-dell-ovaio-e-dell-endometrio/ 2026-06-03T16:41:40.593Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-annuncia-dati-positivi-per-il-candidato-vaccino-meningococcico-5-in-1-abcwy/ 2026-06-03T16:41:55.923Z https://it.gsk.com/it-it/media/comunicati-stampa/gvgh-15-anni-dedicati-alla-salute-globale/ 2026-06-03T16:42:00.49Z https://it.gsk.com/it-it/media/comunicati-stampa/covid-trattamento-precoce-dei-fragili-anticorpi-monoclonali-ancora-efficaci/ 2026-06-03T16:41:58.547Z https://it.gsk.com/it-it/media/comunicati-stampa/terapia-di-precisione-per-le-malattie-eosinofile-si-fa-in-quattro/ 2026-06-03T16:41:59.05Z https://it.gsk.com/it-it/media/comunicati-stampa/parere-positivo-del-chmp-per-il-candidato-vaccino-per-gli-adulti-anziani-contro-il-virus-respiratorio-sinciziale-di-gsk/ 2026-06-03T16:42:00.903Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-italia-piu-tempo-per-i-momenti-che-contano/ 2026-06-03T16:42:14.61Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-condivide-dati-positivi-sul-suo-vaccino-per-adulti-piu-anziani-contro-il-virus-respiratorio-sinciziale-rsv/ 2026-06-03T16:42:13.89Z https://it.gsk.com/it-it/media/comunicati-stampa/nuovi-dati-efficacia-del-vaccino-gsk-nella-prevenzione-dell-herpes-zoster/ 2026-06-03T16:42:15.937Z https://it.gsk.com/it-it/media/comunicati-stampa/giornata-mondiale-contro-la-meningite-i-risultati-di-una-survey-internazionale-di-ipsos/ 2026-06-03T16:42:15.567Z https://it.gsk.com/it-it/media/comunicati-stampa/via-libera-ue-allutilizzo-in-prima-linea-di-dostarlimab-in-combinazione-con-la-chemioterapia-nel-cancro-dellendometrio/ 2026-06-03T16:45:17.803Z https://it.gsk.com/it-it/media/comunicati-stampa/mieloma-multiplo-la-combinazione-belantamab-bortexomib-e-desametasone-aumenta-la-sopravvivenza-libera-da-malattia/ 2026-06-03T16:42:31.87Z https://it.gsk.com/it-it/media/comunicati-stampa/global-health-e-salute-per-il-futuro-la-via-della-prevenzione-20/ 2026-06-03T16:42:37.163Z https://it.gsk.com/it-it/media/comunicati-stampa/mielofibrosi-via-libera-della-commissione-europea-a-momelotinib/ 2026-06-03T16:42:37.54Z https://it.gsk.com/it-it/media/comunicati-stampa/dreamm-7-la-combinazione-con-belantamab-mafodotin-ha-quasi-triplicato-la-sopravvivenza-media-libera-da-progressione/ 2026-06-03T16:42:36.703Z https://it.gsk.com/it-it/media/comunicati-stampa/lo-studio-ruby-mostra-il-potenziale-delle-combinazioni-di-dostarlimab/ 2026-06-03T16:42:38.333Z https://it.gsk.com/it-it/media/comunicati-stampa/vax-corner-online-il-nuovo-portale-sulle-vaccinazioni-per-gli-operatori-sanitari/ 2026-06-03T16:42:49.937Z https://it.gsk.com/it-it/media/comunicati-stampa/parere-positivo-chmp-per-vaccino-contro-il-rsv/ 2026-06-03T16:42:49.333Z https://it.gsk.com/it-it/media/comunicati-stampa/la-commissione-europea-approva-lindicazione-di-eta-estesa-per-arexvy/ 2026-06-03T16:42:48.03Z https://it.gsk.com/it-it/media/comunicati-stampa/ultimi-dati-su-depemokimab-ad-ers-2024/ 2026-06-03T16:45:16.86Z https://it.gsk.com/it-it/media/comunicati-stampa/gsk-presenta-dati-positivi-per-il-vaccino-contro-rsv/ 2026-06-03T16:45:16.52Z https://it.gsk.com/it-it/media/comunicati-stampa/io-ema-e-tu-una-piazza-virtuale-per-conoscere-i-tumori-del-sangue/ 2026-06-03T16:43:10.823Z https://it.gsk.com/it-it/media/comunicati-stampa/comunicato-stampa-gsk-italia-del-10112024/ 2026-06-03T16:43:11.18Z https://it.gsk.com/it-it/media/comunicati-stampa/comunicato-stampa-gsk-italia-11122024/ 2026-06-03T16:43:10.363Z https://it.gsk.com/it-it/media/comunicati-stampa/tumore-dell-endometrio-via-libera-della-commissione-europea-all-utilizzo-di-dostarlimab-piu-chemioterapia/ 2026-06-03T16:43:11.547Z https://it.gsk.com/it-it/media/comunicati-stampa/momelotinib-una-nuova-terapia-per-la-mielofibrosi/ 2026-06-03T16:45:16.107Z https://it.gsk.com/it-it/media/comunicati-stampa/fuoco-di-sant-antonio-non-facciamo-gli-struzzi/ 2026-06-03T16:43:22.593Z https://it.gsk.com/it-it/media/comunicati-stampa/tumore-dell-endometrio-via-libera-in-prima-linea-alla-combinazione-immunoterapia-e-chemioterapia/ 2026-06-03T16:45:17.393Z https://it.gsk.com/it-it/media/comunicati-stampa/mieloma-multiplo-triplicata-sopravvivenza-libera-da-progressione-con-una-terapia-a-tre-farmaci/ 2026-06-03T16:45:40.25Z https://it.gsk.com/it-it/media/comunicati-stampa/approvate-dallue-nuove-combinazioni-con-belentamab-mafodotin/ 2026-06-03T16:47:06.507Z https://it.gsk.com/it-it/media/comunicati-stampa/presente-e-futuro-della-copd-stability/ 2026-06-03T16:46:31.903Z https://it.gsk.com/it-it/media/comunicati-stampa/studio-italiano-dimostra-il-ripristino-delle-alterazioni-del-tessuto-nasale-in-rinosinusite-cronica-con-poliposi-nasale-con-lanticorpo-monoclonale-anti-interleuchina-5-il-5/ 2026-06-03T16:45:58.24Z https://it.gsk.com/it-it/media/comunicati-stampa/incontro-con-il-nuovo-general-manager-di-gsk-italia/ 2026-06-03T16:45:58.91Z https://it.gsk.com/it-it/media/comunicati-stampa/bpco-la-malattia-invisibile-che-si-sente-l-impatto-su-pazienti-famiglie-e-sanita-pubblica/ 2026-06-03T16:45:39.917Z https://it.gsk.com/it-it/media/comunicati-stampa/il-vaccino-contro-il-virus-respiratorio-sinciziale-rsv-di-gsk-ottiene-lapprovazione-europea-per-lestensione-dell-utilizzo-in-tutti-gli-adulti-dai-18-anni-in-su/ 2026-06-03T16:46:00.943Z https://it.gsk.com/it-it/media/comunicati-stampa/approvazione-ema-mepolizumab-in-bpco/ 2026-06-03T16:45:41.933Z https://it.gsk.com/it-it/media/comunicati-stampa/progetto-di-ascolto-sui-pazienti-con-lupus-appena-pubblicato-sul-journal-of-clinical-medicine/ 2026-06-03T16:43:54.777Z https://it.gsk.com/it-it/media/comunicati-stampa/approvazione-ema-depemokimab-asma-grave-e-rinosinusite-cronica-con-poliposi-nasale/ 2026-06-03T16:43:50.59Z https://it.gsk.com/it-it/media/comunicati-stampa/il-vaccino-antirsv-di-gsk-associato-a-riduzioni-di-alcuni-rischi-legati-al-virus-tra-cui-infarto-ictus-e-gravi-riacutizzazioni-di-bpco-e-asma-a-dimostrarlo-uno-studio-real-world/ 2026-06-03T16:43:50.243Z https://it.gsk.com/it-it/media/comunicati-stampa/tumore-dell-endometrio-aifa-approva-l-estensione-dell-immunoterapia-con-dostarlimab/ 2026-06-03T16:43:51.83Z https://it.gsk.com/it-it/media/comunicati-stampa/la-scommessa-green-di-gsk-a-siena-e-rosia-oltre-23-milioni-di-euro-di-investimenti-sulla-sostenibilita/ 2026-06-03T16:43:49.87Z https://it.gsk.com/it-it/media/comunicati-stampa/innovazione-accessibile-la-sfida-che-vale-salute-e-pil/ 2026-06-03T16:43:56.103Z https://it.gsk.com/it-it/media/media-contacts/ 2026-06-03T16:43:56.463Z https://it.gsk.com/it-it/media/rss/ 2026-06-03T16:45:57.943Z https://it.gsk.com/it-it/lavora-con-noi/ 2026-06-03T16:45:59.993Z https://it.gsk.com/it-it/lavora-con-noi/lavorare-in-gsk/ 2026-06-03T16:46:01.507Z https://it.gsk.com/it-it/lavora-con-noi/lavorare-in-gsk/lo-smart-working-in-gsk/ 2026-06-03T16:47:59.96Z https://it.gsk.com/it-it/lavora-con-noi/candidati-con-esperienza/ 2026-06-03T16:48:03.193Z https://it.gsk.com/it-it/lavora-con-noi/studenti-e-neolaureati/ 2026-06-03T16:48:00.88Z https://it.gsk.com/it-it/lavora-con-noi/le-posizioni-aperte-in-italia/ 2026-06-03T16:48:01.157Z https://it.gsk.com/it-it/contattaci/ 2026-06-03T16:47:59.307Z https://it.gsk.com/it-it/contattaci/fornitori/ 2026-06-03T16:48:14.907Z https://it.gsk.com/it-it/condizioni-per-lutilizzo/ 2026-06-03T16:48:17.643Z https://it.gsk.com/it-it/accessibilita/ 2026-06-03T16:48:14.28Z https://it.gsk.com/it-it/accessibilita/report-accessibilita/ 2026-06-03T16:48:14.577Z https://it.gsk.com/it-it/cookie-policy/ 2026-06-03T16:48:13.077Z https://it.gsk.com/it-it/informativa-sulla-privacy/ 2026-06-03T16:48:34.497Z https://it.gsk.com/it-it/dove-siamo/ 2026-06-03T16:48:33.6Z https://it.gsk.com/it-it/cerca-in-gsk/ 2026-06-03T16:48:33.16Z https://it.gsk.com/it-it/sitemap/ 2026-06-03T16:48:32.95Z https://it.gsk.com/it-it/errore-404/ 2026-06-03T16:48:33.38Z